Matrix metalloproteinases in health and disease: Insights from dermatopathology

American Journal of Dermatopathology

Volumn 34, Issue 6, 2012, Pages 565-579

  Hernández Pérez, Marier ^a   Mahalingam, Meera ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cutaneous pathology; matrix metalloproteinases

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 21; MATRIX METALLOPROTEINASE 24; MATRIX METALLOPROTEINASE 25; MATRIX METALLOPROTEINASE 26; MATRIX METALLOPROTEINASE 28; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; BASAL CELL CARCINOMA; CELL DIFFERENTIATION; CELL GROWTH; CELL INVASION; CELL MIGRATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; KERATINOCYTE; MACROPHAGE; MELANOMA; MOLECULAR CLONING; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYODERMA GANGRENOSUM; REVIEW; SKIN DISEASE; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; STROMA; TUMOR;

EMBRYONIC DEVELOPMENT; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASES; SKIN; SKIN DISEASES; SKIN NEOPLASMS; SKIN PHYSIOLOGICAL PHENOMENA;

EID: 84864343593     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e31821e8744     Document Type: Review

References (75)

1. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009;27:5287-5295.
2. Kerkela E, Saarialho-Kere U. Matrix metalloproteinases in tumor progression: Focus on basal and squamous cell skin cancer. Exp Dermatol. 2003;12:109-125. (Pubitemid 36934696)
3. Pilcher BK, Sudbeck BD, Dumin JA, et al. Collagenase-1 and collagen in epidermal repair. Arch Dermatol Res. 1998;290(Suppl):37-46.
4. Van Lint P, Libert C. Matrix metalloproteinase-8: Cleavage can be decisive. Cytokine Growth Factor Rev. 2006;17:217-223. (Pubitemid 44038613)
5. Wu W, Mwale F, Tchetina E, et al. Cartilage matrix resorption in skeletogenesis. Novartis Found Symp. 2001;232:158-170.
6. Ravanti L, Häkkinen L, Larjava H, et al. Transforming growth factor-beta induces collagenase-3 expression by human gingival fibroblasts via p38 mitogen-activated protein kinase. J Biol Chem. 1999;274:37292-37300.
7. Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol. 2003;28:12-24. (Pubitemid 36017046)
8. Mirastschijski U, Impola U, Jahkola T, et al. Ectopic localization of matrix metalloproteinase-9 in chronic cutaneous wounds. Hum Pathol. 2002;33: 355-364. (Pubitemid 34461471)
9. McCawley LJ, Wright J, LaFleur BJ, et al. Keratinocyte expression of MMP3 enhances differentiation and prevents tumor establishment. Am J Pathol. 2008;173:1528-1539.
10. Rechardt O, Elomaa O, Vaalamo M, et al. Stromelysin-2 is upregulated during normal wound repair and is induced by cytokines. J Invest Dermatol. 2000;115:778-787.
11. Wei L, Shi YB. Matrix metalloproteinase stromelysin-3 in development and pathogenesis. Histol Histopathol. 2005;20:177-185. (Pubitemid 40028996)
12. Kerkelä E,Böhling T, Herva R, et al. Human macrophage metalloelastase (MMP-12) expression is induced in chondrocytes during fetal development and malignant transformation. Bone. 2001;29:487-493. (Pubitemid 33026470)
13. Saarialho-Kere U, Crouch EC, Parks WC. Matrix Metalloproteinase Matrilysin is constitutively expressed in adult human exocrine epithelium. J Invest Dermatol. 1995;105:190-196.
14. Ahokas K, Skoog T, Suomela S, et al. Matrilysin-2 (matrix metalloproteinase- 26) is upregulated in keratinocytes during wound epair and early skin carcinogenesis. J Invest Dermatol. 2005;124:849-856. (Pubitemid 40489514)
15. Osenkowski P, Toth M, Fridman R. Processing, shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP). J Cell Physiol. 2004;200:2-10. (Pubitemid 38720616)
16. Bjørn SF, Hastrup N, Larsen JF, et al. Messenger RNA for membrane-type 2 matrix metalloproteinase, MT2-MMP, is expressed in human placenta of first trimester. Placenta. 2000;21:170-176. (Pubitemid 30240782)
17. Lang R, Braun M, Sounni NE, et al. Crystal structure of the catalytic domain of MMP-16/MT3-MMP: Characterization of MT-MMP specific features. J Mol Biol. 2004;336:213-225. (Pubitemid 38102343)
18. Zhao H, Bernardo MM, Osenkowski P, et al. Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 regulates pro-MMP-2 activation. J Biol Chem. 2004;279:8592-8601. (Pubitemid 38295913)
19. Sohail A, Sun Q, Zhao H, et al. MT4-(MMP17) and MT6-MMP (MMP25). A unique set of membrane-anchored matrix metalloproteinases: Properties and expression in cancer. Cancer Metastasis Rev. 2008; 27:289-302.
20. Gauthier MC, Racine C, Ferland C, et al. Expression of membrane type-4 matrix metalloproteinase (metalloproteinase-17) by human eosinophils. Int J Biochem Cell Biol. 2003;35:1667-1673. (Pubitemid 37297413)
21. Pei D. Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP. J Biol Chem. 1999;274:8925-8932. (Pubitemid 29164694)
22. Llano E, Pendás AM, Freije JP, et al. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. Cancer Res. 1999;59:2570-2576. (Pubitemid 29269100)
23. Impola U, Toriseva M, Suomela S, et al. Matrix metalloproteinase-19 is expressed by proliferating epithelium but disappears with neoplastic dedifferentiation. Int J Cancer. 2003;103:709-716. (Pubitemid 36110225)
24. Boyd S, Virolainen S, Pärssinen J, et al. MMP-10 (Stromelysin-2) and MMP-21 in human and murine squamous cell cancer. Mod Pathol. 2006; 19:1203-1212.
25. Saarialho-Kere U, Kerkelä E, Jahkola T, et al. Epilysin (MMP-28) expression is associated with cell proliferation during epithelial repair. J Invest Dermatol. 2002;119:14-21. (Pubitemid 35304384)
26. Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010;20:161-168.
27. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity. Biochim Biophys Acta. 2010;1803: 55-71.
28. Tsukifuji R, Tagawa K, Hatamochi A, et al. Expression of matrix metalloproteinase-1, -2 and -3 in squamous cell carcinoma and actinic keratosis. Br J Cancer. 1999;80:1087-1091. (Pubitemid 29233934)
29. Tsukifuji R, Sakai Y, Hatamochi A, et al. Gene expression of matrix metalloproteinase-1 (interstitial collagenases) and matrix metalloproteinase- 3 (stromelysins-1) in basal cells carcinoma by in situ hybridization using chondroitin ABC lyase. Histochem J. 1997;29:401-407. (Pubitemid 27245091)
30. Blackburn JS, Rhodes CH, Coon CI, et al. RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis. Cancer Res. 2007;67: 10849-10858. (Pubitemid 350145914)
31. Airola K, Karonen T, Vaalamo M, et al. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer. 1999;80:733-743. (Pubitemid 29209836)
32. Nikkola J, Vihinen P, Vuoristo MS, et al. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res. 2005;11:5158-5166. (Pubitemid 41003701)
33. Massi D, Franchi A, Ketabchi S, et al. Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin. Hum Pathol. 2003;34: 80-88. (Pubitemid 36160025)
34. Bister V, Mäkitalo L, Jeskanen L, et al. Expression of MMP-9, MMP-10 and TNF-alpha and lack of epithelial MMP-1 and MMP-26 characterize pyoderma gangrenosum. J Cutan Pathol. 2007;34:889-898. (Pubitemid 350132001)
35. Mazzarella N, Femiano F, Gombos F, et al. Matrix metalloproteinase gene expression in oral lichen planus: Erosive vs. reticular forms. J Eur Acad Dermatol Venereol. 2006;20:953-957.
36. Fisher GJ, Datta SC, Talwar HS, et al. Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature. 1996;379: 335-339. (Pubitemid 26033074)
37. Varani J, Warner RL, Gharaee-Kermani M, et al. Vitamin A antagonizes decreased cell growth and elevated collagen-degrading matrix metalloproteinases and stimulates collagen accumulation in naturally aged human skin. J Invest Dermatol. 2000;114:480-486. (Pubitemid 30415333)
38. Varani J, Hattori Y, Chi Y, et al. Collagenolytic and gelatinolytic matrix metalloproteinases and their inhibitors in basal cell carcinoma of skin: Comparison with normal skin. Br J Cancer. 2000;82:657-665. (Pubitemid 30085205)
39. Moilanen M, Pirila E, Grenman R, et al. Expression and regulation of collagenase-2 (MMP-8) in head and neck squamous cell carcinomas. J Pathol. 2002;197:72-81. (Pubitemid 34450166)
40. Vihinen P, Koskivuo I, Syrjänen K, et al. Serum matrix metalloproteinase- 8 is associated with ulceration and vascular invasion of malignant melanoma. Melanoma Res. 2008;18:268-273.
41. Johansson N, Airola K, Grenman R, et al. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol. 1997;151:499-508. (Pubitemid 27330069)
42. Kuivanen TT, Jeskanen L, Kyllönen L, et al. Transformation-specific matrix metalloproteinases, MMP-7 and MMP-13, are present in epithelial cells of keratoacanthomas. Mod Pathol. 2006;19:1203-1212. (Pubitemid 44268190)
43. Kivisaari AK, Kallajoki M, Mirtti T, et al. Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas. Br J Dermatol. 2008;158:778-785. (Pubitemid 351415753)
44. Niimi Y, Pawankar R, Kawana S. Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase- 13 in lesional skin of bullous pemphigoid. Int Arch Allergy Immunol. 2006;139:104-113. (Pubitemid 43177321)
45. Papakonstantinou E, Aletras AJ, Glass E, et al. Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin. J Invest Dermatol. 2005;125:673-684.
46. O'Grady A, Dunne C, O'Kelly P, et al. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression. Histopathology. 2007;51:793-804. (Pubitemid 350179420)
47. Simonetti O, Lucarini G, Brancorsini D, et al. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer. 2002;95:1963-1970. (Pubitemid 35222177)
48. Vaisanen A, Tuominen H, Kalionen M, et al. Matrix metalloproteinases 2 (72kD Type IV collagenases) expression occurs in the early stage of human melanocytic tumor progression and may have a prognostic value. J Pathol. 1996;180:283-289.
49. Weinrach DM, Wang KL, Wiley EL, et al. Immunohistochemical expression of matrix metalloproteinases 1, 2, 9, and 14 in dermatofibrosarcoma protuberans and common fibrous histiocytoma (dermatofibroma). Arch Pathol Lab Med. 2004;128:1136-1141. (Pubitemid 39313367)
50. Zarbock R, Hendig D, Szliska C, et al. Analysis of MMP2 promoter polymorphisms in patients with pseudoxanthoma elasticum. Clin Chim Acta. 2010;411:1487-1490.
51. Bongiorno MR, Doukaki S, Ferro G, et al. Matrix metalloproteinases 2 and 9, and extracellular matrix in Kaposi's sarcoma. Dermatol Ther. 2010; 23(Suppl 2):S33-S36.
52. Zhong S, Yang G, Xia C, et al. Expression of matrix metalloproteinase and its tissue inhibitor in haemangioma. J Huazhong Univ Sci Technolog Med Sci. 2009;29:614-619.
53. Vasku A, Vasku JB, Necas M, et al. Matrix metalloproteinase-2 promoter genotype as a marker of cutaneous T-cell lymphoma early stage. J Biomed Biotechnol. 2010;2010:805-907.
54. Verdolini R, Amerio P, Goteri G, et al. Cutaneous carcinomas and preinvasive neoplastic lesions. Role of MMP-2 and MMP-9 metalloproteinases in neoplastic invasion and their relationship with proliferative activity and p53 expression. J Cutan Pathol. 2001;28:120-126. (Pubitemid 32112995)
55. Van den Oord JJ, Paemen L, Opdenakker G, et al. Expression of gelatinase B and extracellular matrix metalloproteinase inducer EMMPRIM in benign and malignant pigment cell lesions of the skin. Am J Pathol. 1997; 151:665-670. (Pubitemid 27385597)
56. MacDougall JR, Bani MR, Lin Y, et al. Proteolytic switching: opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B expression. Br J Cancer. 1999;80:504-512. (Pubitemid 29213207)
57. Tedeschi A, Asero R, Lorini M, et al. Plasma levels of matrix metalloproteinase-9 in chronic urticaria patients correlate with disease severity and C-reactive protein but not with circulating histaminereleasing factors. Clin Exp Allergy. 2010;40:875-881.
58. Suomela S, Kariniemi AL, Snellman E, et al. Metalloelastase (MMP- 12) and 92-kDa gelatinase (MMP-9) as well as their inhibitors, TIMP-1 and -3, are expressed in psoriatic lesions. Exp Dermatol. 2001;10: 175-883.
59. Zhao Z, Chang H, Trevino RP, et al. Selective up-regulation of matrix metalloproteinase-9 expression in human erythema migrans skin lesions of acute lyme disease. J Infect Dis. 2003;188:1098-1104. (Pubitemid 37338972)
60. Rasheed H, Tolba-Fawzi MM, Abdel-Halim MR, et al. Immunohistochemical study of the expression of matrix metalloproteinase-9 in skin lesions of mycosis fungoides. Am J Dermatopathol. 2010;32:162-169.
61. Sardy M. Role of matrix metalloproteinases in skin ageing. Connect Tissue Res. 2009;50:132-138.
62. Son KD, Kim TJ, Lee YS, et al. Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin. J Surg Oncol. 2008;97:615-620.
63. Tas F, Duranyildiz D, Oguz H, et al. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma. Med Oncol. 2005;22:39-44. (Pubitemid 40647228)
64. Nikkola J, Vihinen P, Vlaykova T, et al. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer. 2002;97:432-438. (Pubitemid 34027800)
65. Bodey B, Bodey B Jr, Siegel SE, et al. Matrix metalloproteinase expression in malignant melanomas: Tumor-extracellular matrix interactions in invasion and metastasis. In Vivo. 2000;15:57-64.
66. Suomela S, Koljonen V, Skoog T, et al. Expression of MMP-10, MMP-21, MMP-26, and MMP-28 in Merkel cell carcinoma. Virchows Arch. 2009; 455:495-503.
67. Asch PH, Basset P, Roos M, et al. Expression of stromelysin 3 in keratoacanthoma and squamous cell carcinoma. Am J Dermatopathol. 1999;21:146-150. (Pubitemid 29162873)
68. Majmudar G, Nelson BR, Jensen TC, et al. Increased expression of stromelysin-3 in basal cell carcinomas. Mol Carcinog. 1994;9:17-23. (Pubitemid 24061281)
69. Thewes M, Worret WI, Engst R, et al. Stromelysin-3 (ST-3): immunohistochemical characterization of the matrix metalloproteinase (MMP)-11 in benign and malignant skin tumours and other skin disorders. Clin Exp Dermatol. 1999;24:122-126.
70. Kim HJ, Lee JY, Kim SH, et al. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: Comparison with factor XIIIa and CD34. Br J Dermatol. 2007;157:319-324. (Pubitemid 47083868)
71. Kerkelä E, Ala-Aho R, Jeskanen L, et al. Expression of human macrophage metalloelastase (MMP-12) by tumor cells in skin cancer. J Invest Dermatol. 2000;114:1113-1119. (Pubitemid 30415226)
72. Fernandez-Figueras MT, Puig L, Musulen E, et al. Expression profiles associated with aggressive behavior in Merkel cell carcinoma. Mod Pathol. 2007;20:90-101. (Pubitemid 44967954)
73. Igondjo-Tchen-Changotade S, Assoumou A, Gueniche F, et al. Epigallocatechin gallate's protective effect against MMP7 in recessive dystrophic epidermolysis bullosa patients. J Invest Dermatol. 2007;127: 821-828. (Pubitemid 46434659)
74. Kerkelä E, Ala-aho R, Jeskanen L, et al. Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancers. Br J Cancer. 2001;84:659-669. (Pubitemid 32239000)
75. Kondratiev S, Gnepp DR, Yakirevich E, et al. Expression and prognostic role of MMP2, MMP9, MMP13, and MMP14 matrix metalloproteinases in sinonasal and oral malignant melanomas. Hum Pathol. 2008;39: 337-343. (Pubitemid 351186686)